今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

港股汽车股强势反弹，比亚迪股份涨幅超6%

香港 - 6月13日，港股市场迎来反弹，恒生指数上涨0.97%，其中汽车股表现强劲，比亚迪股份（01211）涨幅超6%，成为当日市场焦点。

比亚迪股份股价强劲反弹，主要有以下几个原因：

• 欧盟关税调整利好比亚迪出口。 花旗银行近日发布研报表示，欧盟将关税上调至20%，对比亚迪略有利好，改善了比亚迪今年第二季度及第三季度出口增长预期。
• 比亚迪销量持续增长。 据比亚迪最新发布的产销数据，5月比亚迪共生产和销售新能源汽车23.4万辆，同比分别增长52.4%和51.6%。其中，纯电动乘用车生产和销售分别为17.2万辆和16.4万辆，同比分别增长65.8%和60.5%。
• 投资者对新能源汽车市场前景看好。 在全球能源转型和碳中和的大趋势下，新能源汽车市场需求旺盛，预计未来将保持快速增长。比亚迪作为全球领先的新能源汽车厂商，有望充分受益于市场红利。

除比亚迪股份外，其他港股汽车股也普遍上涨，吉利汽车（00175）上涨2.02%，长城汽车（02333）上涨1.72%，蔚来汽车（09866）上涨1.68%。

业内人士表示，随着新能源汽车市场需求的不断增长，以及各车企新产品的陆续推出，港股汽车股有望继续保持强劲表现。